Drug intelligence / Profile preview

CTX020

Development stage: Preclinical
Lead developer: Character Biosciences

Overview

CTX020 is an investigational, preclinical-stage therapeutic candidate originally developed by Clover Therapeutics (which rebranded as Character Biosciences in May 2022) for the treatment of both dry and wet age-related macular degeneration (AMD). Developed using a precision medicine platform that integrates genomics, clinical data, and machine learning, CTX020 aims to target underlying genetic drivers of AMD. However, the specific molecular target, mechanism of action, and modality of CTX020 remain undisclosed by the developer.

Beyond the preview

Go deeper on CTX020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX020.

Explore the full profile